This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ABT-143, rosuvastatin/choline fenofibrate (Hexa, ABT-335), Crestor/TriLipix
Description: The active ingredient of Crestor, rosuvastatin calcium, inhibits HMG-CoA reductase, an enzyme required for the synthesis of cholesterol.
TriLipix (Hexa is Solvay's name for the drug) is a next generation fenofibrate (TriCor). Fenofibrate activates peroxisome proliferator activated receptor alpha (PPAR alpha). The activation of PPAR alpha leads to the induction of lipoprotein lipase and the elimination of triglyceride-rich particles from plasma.
Deal Structure: Abbott and AstraZeneca announced in July 2006 a collaboration to co-develop and market a combination treatment that will target all three important blood lipids LDL-C bad cholesterol, HDL-C good cholesterol, and triglycerides in one single pill as part of a comprehensive treatment regimen. Under the agreement, the companies will initiate two parallel programs: a CRESTOR/TriCor fixed-dose combination and a CRESTOR/TriLipix combination. The overall intention of the agreement is for the two companies broadly to share development costs and profits over the duration of the collaboration. Abbott will execute the clinical trial program and be responsible for regulatory registration of the new combination therapy. AstraZeneca will hold the New Drug Application (NDA).
AstraZeneca licensed Crestor from Shionogi in 1998. On May 16, 2002, the two companies announced an agreement to co-market Crestor in Japan.
In September 2009, Solvay announced that its Board of Directors has decided to...See full deal structure in Biomedtracker
Partners: AstraZeneca PLC Shionogi & Co. Ltd.
Additional information available to subscribers only: